Summary
Aim
The aim of this study is to evaluate the weight loss effect of intragastric balloon (IB) application in patients with different body mass indexes (BMI) in the treatment of obesity.
Methods
Between 2005 and 2010, out of 251 obese patients treated with liquid-filled IB in our center, 220 obese patients in whom the balloons were removed after 180 days, aged 15–64 years and mean BMI 38.73 kg/m2 (27.01–77.16) were evaluated. The data of patients [weight, BMI, excess weight loss percentage (EWL%) and excess BMI loss percentage (EBMIL%) changes] at the day of insertion, at the day of removal and at sixth month of the removal were compared, according to their BMI indexes.
Results
The weight changes and BMIs of the patients had significantly decreased at the removal and at sixth month after the removal compared to the beginning (p < 0.01). However, the raise in the weights and BMIs at sixth month after the removal are also statistically significant (p < 0.01). The total weight losses, EWL% and EBMIL% according to BMI index groups are significantly decreased at removal compared to the beginning (p < 0.01). This significance is more prominent for patients with BMI 27–35 kg/m2.
Conclusions
IB can be used alone for patients with BMI < 35 kg/m2 to overcome obesity as a successful single stage procedure. However, for patients with BMI > 35 kg/m2 IB application should be combined with a surgical bariatric procedure to achieve a sustainable weight loss.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Deitel M. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg. 2003;13:329–30. PMID:12852397 doi:10.1381/096089203765887598.
Mazure RA, Salgado G, Villareal P, Cobo B, Valencia A, Culebras JM. Intragastric balloon and multidisciplinary team. Nutr Hosp. 2009;24:282–7. PMID:19721900
Buchwald H. Consensus Conference Statement Bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. J Am Coll Surg. 2005;200:593–604. PMID:16925250 doi:10.1016/j.soard.2005.04.002.
Fried M, Hainer V, Basdevant A, et al. Interdisciplinary European guidelines for surgery for severe (morbid) obesity. Obes Surg. 2007;17:260–70. PMID:17476884 doi:10.1007/s11695-007-9025-2.
Carvalho GL, Barros CB, Okazaki M, et al. An improved intragastric balloon procedure using a new balloon: preliminary analysis of safety and efficacy. Obes Surg. 2009;19:237–42. PMID:18581191 doi:10.1007/s11695-008-9592-x.
Coskun H, Aksakal C. Experience with sedation technique for intragastric balloon placement and removal. Obes Surg. 2007;17:995–6. PMID:17894166 doi:10.1007/s11695-007-9158-3.
Coskun H, Bozkurt S. A case of asymptomatic fungal and bacterial colonization of an intragastric balloon. World J Gastroenterol. 2009;15:5751–3. PMID:19960576 doi:10.3748/wjg.15.5751.
Imaz I, Martinez-Cervell C, Garcia-Alvarez EE, Sendra-Gutierrez JM, Gonzalez-Enriquez J. Safety and effectiveness of the intragastric balloon for obesity. A meta-analysis. Obes Surg. 2008;18:841–6. PMID:18459025 doi:10.1007/s11695-007-9331-8.
De Waele B, Reynaert H, Urbain D, Willems G. Intragastric balloons for preoperative weight reduction. Obes Surg. 2000;10:58–60. PMID:10715647 doi:10.1381/09608920060674139.
Genco A, Cipriano M, Materia A, et al. Laparoscopic sleeve gastrectomy versus intragastric balloon: a case-control study. Surg Endosc. 2009;23:1849–53. PMID:19169745 doi:10.1007/s00464-008-0285-2.
Herve J, Wahlen CH, Schaeken A, et al. What becomes of patients one year after the intragastric balloon has been removed? Obes Surg. 2005;15:864–70. PMID:15978160 doi:10.1381/0960892054222894.
Weiner R, Gutberlet H, Bockhorn H. Preparation of extremely obese patients for laparoscopic gastric banding by gastric-balloon therapy. Obes Surg. 1999;9:261–4. PMID:10484312 doi:10.1381/096089299765553133.
Forlano R, Ippolito AM, Iacobellis A, et al. Effect of the BioEnterics intragastric balloon on weight, insulin resistance, and liver steatosis in obese patients. Gastrointest Endosc. 2010;71:927–33 PMID:19863955 doi:10.1016/j.gie.2009.06.036.
Crea N, Pata G, Della Casa D, et al. Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis. Obes Surg. 2009;19:1084–8. PMID:19506981 doi:10.1007/s11695-009-9879-6.
Ricci G, Bersani G, Rossi A, Pigo F, De Fabritiis G, Alvisi V. Bariatric therapy with intragastric balloon improves liver dysfunction and insulin resistance in obese patients. Obes Surg. 2008;18:1438–42. PMID:18369681 doi:10.1007/s11695–008-9487-x.
Mui WL, Ng EK, Tsung BY, Lam CH, Yung MY. Impact on obesity-related illnesses and quality of life following intragastric balloon. Obes Surg. 2010;20:1128–32. PMID:19015930 doi:10.1007/s11695-008-9766-6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bozkurt, S., Coskun, H. The early results of intragastric balloon application of different BMI groups. Eur Surg 44, 383–387 (2012). https://doi.org/10.1007/s10353-012-0167-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10353-012-0167-7